Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Patent covering oral spray drug delivery technology, for the treatment of insomnia
Subscribe to our email newsletter
The US Patent and Trademark Office (USPTO) has issued a notification to NovaDel Pharma (NovaDel) for a new US Patent No. 7632517, entitled Buccal, Polar and Non-polar Spray Containing Zolpidem. It covers a method of treating insomnia by administering zolpidem to humans utilising NovaDel’s oral spray technology.
As previously announced, NovaDel’s Zolpimist (zolpidem tartrate) 5mg and 10mg oral spray product is approved by the FDA for the short-term treatment of insomnia characterised by difficulties with sleep initiation.
Zolpimist is NovaDel’s second product approved by the FDA that uses NovaDel’s NovaMist oral spray technology. Zolpimist contains zolpidem tartrate, the same active ingredient as Ambien, for the treatment of insomnia.
The company said that with the issuance of this patent, it has been granted nine patents in the US, three patents in Canada and 66 patents throughout Europe, including Austria, Belgium, Denmark, Finland, France, Germany, Great Britain, Greece, Ireland, Italy, Luxembourg, Monaco, Netherlands, Portugal, Spain, Sweden and Switzerland. Additionally, NovaDel has over 80 patents pending around the globe.